HACKENSACK, N.J., March 24 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced today that the Company will host a corporate booth and present five posters at the American Pain Society’s 25th Annual Scientific Meeting in San Antonio, Texas to be held May 3-6, 2006. The DOV posters and published abstracts will focus on bicifadine, the Company’s novel analgesic, and provide additional information and scientific data, including:
* Bicifadine as an efficacious analgesic in animal models of neuropathic pain * Characterization of bicifadine’s molecular pharmacology and efficacy in animal models of acute pain * An overview of data from the completed Phase III trial of bicifadine and tramadol versus placebo in the treatment of postoperative bunionectomy pain * An overview of data from the ongoing Phase III open label safety and efficacy trial of bicifadine for the treatment of chronic low back pain * Data regarding single-dose and repeat-dose bicifadine pharmacokinetics in healthy adult male human subjects
Members of the DOV preclinical research, clinical development and senior management teams will be attending the conference and will be available to discuss the posters with meeting attendees.
DOV also announced today that Dr. Phil Skolnick, CSO and Senior Vice President of Research, will present at the 4th Annual Psychiatric Disorders in Drug Discovery & Development Conference to be held in Boston on March 27-28, 2006. Additionally, the Company will make presentations at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to be held in New York City on April 4-5, 2006 and at the UBS Global Pharmaceuticals Conference to be held in New York City on April 24-25, 2006. DOV presentations will be archived and available on the Investor Relations section of the Company’s Web site, http://www.dovpharm.com, for 90 days following the conferences.
More details about these events and upcoming conferences at which DOV will present can be found on the Calendar section of the Company’s Web site. Interested parties should consult the DOV Web site for such details as the Company may announce its participation in such events and conferences via the Web site, and not press releases, in the future.
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain and depression. Our partner Neurocrine has filed two NDAs for the use of DOV’s compound indiplon for the treatment of insomnia.
DOV Pharmaceutical, Inc.
CONTACT: Keri Mattox, Director, Investor Relations and CorporateCommunications of DOV Pharmaceutical, Inc. +1-201-968-0980
Web site: http://www.dovpharm.com/
